GHRS Stock Summary and Trading Ideas (GH Research PLC - | NASDAQ:GHRS)

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

GH Research PLC - trades on the NASDAQ stock market under the symbol GHRS.

As of April 10, 2026, GHRS stock price climbed to $15.72 with 120,100 million shares trading.

GHRS has a beta of 1.76, meaning it tends to be more sensitive to market movements. GHRS has a correlation of 0.16 to the broad based SPY ETF.

GHRS has a market cap of $975.08 million. This is considered a Small Cap stock.

In the last 3 years, GHRS traded as high as $20.50 and as low as $5.05.

The top ETF exchange traded funds that GHRS belongs to (by Net Assets): IBB, PSIL, EIRL, BBC, GWX.

GHRS has outperformed the market in the last year with a price return of +81.5% while the SPY ETF gained +30.9%. GHRS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +4.7% and +19.5%, respectively, while the SPY returned -1.8% and +7.2%, respectively.

GHRS support price is $14.59 and resistance is $15.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GHRS shares will trade within this expected range on the day.